[{"orgOrder":0,"company":"ImPact Biotech","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2024","type":"Funding","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImPact Biotech \/ EIC Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ EIC Accelerator"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Steba Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Steba Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase I","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase I","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase III","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ImPact Biotech \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Padeliporfin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : The company's primary product candidate, WST11 (padeliporfin), is undergoing evaluation in a pivotal Phase 3 clinical trial with patients for treating low-grade upper tract urothelial carcinoma.

                          Product Name : WST11

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          September 27, 2024

                          Lead Product(s) : Padeliporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AAPS National Biotech
                          Not Confirmed
                          AAPS National Biotech
                          Not Confirmed

                          Details : The funds will used to advance the company-lead product WST11 (padeliporfin). Currently, it is being evaluated in late-stage clinical trials for treating low-grade upper tract urothelial cancer.

                          Product Name : WST11

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Undisclosed

                          July 24, 2024

                          Lead Product(s) : Padeliporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : EIC Accelerator

                          Deal Size : $14.6 million

                          Deal Type : Funding

                          blank

                          03

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : WST11 (padeliporfin VTP) is a vascular targeted photodynamic therapy which is a minimally invasive oncology platform, it is being investigated for Low Grade Upper Tract Urothelial Cancer.

                          Product Name : WST11

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          June 05, 2024

                          Lead Product(s) : Padeliporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : The company's primary product candidate, WST11 (padeliporfin), is presently undergoing evaluation in a pivotal Phase 3 clinical trial with patients for low-grade upper tract urothelial carcinoma.

                          Product Name : WST11

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          April 24, 2024

                          Lead Product(s) : Padeliporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : The company's primary product candidate, WST11 (padeliporfin), is undergoing evaluation in a pivotal Phase 3 clinical trial with patients for treating low-grade upper tract urothelial carcinoma.

                          Product Name : WST11

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          February 06, 2024

                          Lead Product(s) : Padeliporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : ImPact Biotech is developing padeliporfin vascular targeted photodynamic (VTP) therapy, which is currently being evaluated for the treatment of patients with peripheral lung cancer.

                          Product Name : WST11

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          December 20, 2023

                          Lead Product(s) : Padeliporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : Padeliporfin VTP (vascular targeted photodynamic therapy) is a minimally invasive oncology platform for the treatment of solid tumors and Pancreatic Cancer and has received Fast Track designation and Orphan Drug Designation for adult patients with low-gr...

                          Product Name : WST11

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          May 07, 2023

                          Lead Product(s) : Padeliporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : Padeliporfin VTP (vascular targeted photodynamic therapy) is a minimally invasive oncology platform for the treatment of peripheral lung cancer and pancreatic cancer and has received Fast Track designation and Orphan Drug Designation for adult patients w...

                          Product Name : WST11

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          April 08, 2023

                          Lead Product(s) : Padeliporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : The ENLIGHTED study aims to recruit 100 patients with low-grade UTUC in either the kidney or the ureter. The patients will be treated with Padeliporfin ImPACT in two phases, induction treatment and maintenance treatment, and will be followed up for 1-5 y...

                          Product Name : Padeliporfin ImPACT

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          April 20, 2021

                          Lead Product(s) : Padeliporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Arvo
                          Not Confirmed
                          Arvo
                          Not Confirmed

                          Details : This swiftly follows clearance of the Investigational New Drug (IND) application granted in December 2020 allowing initiation of the pivotal Phase 3 clinical trial of padeliporfin ImPACT in patients with low-grade UTUC, expected to begin enrollment in Q1...

                          Product Name : Padeliporfin ImPACT

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          January 15, 2021

                          Lead Product(s) : Padeliporfin

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank